Recombinant soluble transforming growth factor β type II receptor ameliorates radiation enteropathy in mice

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1286-1296

  Zheng, Huaien ^a   Wang, Junru ^a   Koteliansky, Victor E ^b   Gotwals, Philip J ^b  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; ISOPROTEIN; MESSENGER RNA; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; C57BL MOUSE; CHEMISTRY; CHO CELL; DRUG EFFECT; ENTEROPATHY; GENETICS; HAMSTER; ILEUM; MALE; METABOLISM; MOUSE; PATHOLOGY; RADIATION EXPOSURE; RADIATION INJURY; SOLUBILITY;

ANIMALS; CHO CELLS; COLLAGEN; CRICETINAE; ILEUM; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; INTESTINAL DISEASES; MALE; MICE; MICE, INBRED C57BL; PROTEIN ISOFORMS; RADIATION INJURIES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SOLUBILITY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 0034320191     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19282     Document Type: Article

References (51)

1. Berthrong M, Fajardo LF. Radiation injury in surgical pathology. Part II. Alimentary tract. Am J Surg Pathol 1981;5:153-178.
2. Langberg CW, Hauer-Jensen M, Sung C-C, Kane CJM. Expression of fibrogenic cytokines in rat small intestine after fractionated irradiation. Radiother Oncol 1994;32:29-36.
3. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-l expression in irradiated liver. Radiât Res 1990;122:77-85.
4. Anscher MS, Peters WP, Reisenbichler H, Petras WP, Jirtle RL. Transforming growth factor as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-1598.
5. Barcellos-Hoff MH. Radiation-induced transforming growth factor and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Res 1993:53:3880-3886.
6. Canney PA, Dean S. Transforming growth factor beta: a promotor of late connective tissue injury following radiotherapy? Br J Radiol 1990:63:620-623.
7. Finkelstein JN, Johnston CJ, Baggs R, Rubin P. Early alterations in extracellular matrix and transforming growth factor gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiât Oncol Biol Phys 1994;28:621-631.
8. Kraft M, Oussoren Y, Stewart FA, Dörr W, Schultz-Hector S. Radiation-induced changes in transforming growth factor and collagen expression in the murine bladder wall and its correlation with bladder function. Radiât Res 1996:146:619-627.
9. Randall K, Goggle JE. Long-term expression of transforming growth factor TGFl in mouse skin after localized -irradiation. Int J Radiât Biol 1996:70:351-360.
10. Wang J, Robbins MEC. Radiation-induced alteration of rat mesangial cell transforming growth factor- and expression of the genes associated with the extracellular matrix. Radiât Res 1996; 146:561-568.
11. Hauer-Jensen M, Richter KK, Wang J, Abe E, Sung C-C, Hardin JW. Changes in transforming growth factor l (TGF-l) gene expression and immunoreactivity levels during development of chronic radiation enteropathy. Radiât Res 1998:150:673-680.
12. Wang J, Zheng H, Sung C-C, Richter KK, Hauer-Jensen M. Cellular sources of transforming growth factor (TGF-) isoforms in early and chronic radiation enteropathy. Am J Pathol 1998:153:15311540.
13. Richter KK, Langberg CW, Sung C-C, Hauer-Jensen M. Increased transforming growth factor (TGF-) immunoreactivity is indepen-dently associated with chronic injury in both consequential and primary radiation enteropathy. Int J Radiât Oncol Biol Phys 1997; 39:187-195.
14. Richter KK, Sung C-C, Langberg CW, Hauer-Jensen M. Association of transforming growth factor (TGF-) immunoreactivity with specific histopathologii: lesions in subacute and chronic experimental radiation enteropathy. Radiother Oncol 1996:39:201302.
15. Wang J, Richter KK, Sing C-C, Hauer-Jensen M. Potential role of the mannose 6-phosphate/insulin-like growth factor II receptor in regulating transforming growth factor l tissue specificity in chronic radiation enteropathy. Radiother Oncol 1998:50:205213.
16. Skwarchuk MW, Travis EL. Changes in histology and fibrogenic cytokines in irradiatec colorectum of two murine strains. Int J Radiât Oncol Biol Phys 1998;42:169-178.
17. Massague J. TGF- signal transduction. Annu Rev Biochem 1998;67:753-791.
18. George J, Roulot D, Kcteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sei USA 1999:96:12719-12724.
19. Smith JD, Bryant SR, Couper LL, Vary CPH, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor- type II receptor inhibits nega~:ive remodeling, fibroblast transdifferentiation, and intimai lesion formation but not endothelial growth. Circ Res 1999:84:1212-1222.
20. Wang Q, Wang Y, Hyde' DM, Gotwals PJ, Koteliansky VE, Ryan ST, Giri SN. Reduction of bleomycin induced lung fibrosis by transforming growth factoi soluble receptor in hamsters. Thorax 1999:54:805-812.
21. O'Connor-McCourt M, Segarini P, Grothe S, Tsang MLS, Weatherbee JA. Analysis of-;he interaction between two TGF-binding proteins and three TGF- isoforms using surface plasmon resonance. Ann N Y Acad Sei 1995;766:300-302.
22. Tsang MLS, Zhou L, ZiengBL, Wenker J, Fransen G, Humphrey J, Smith JM, O'Connor-McCourt M, Lucas R, Weatherbee JA. Characterization of recorminant soluble human transforming growth factor- receptor type II (rhTGF-sRIl). Cytokine 1995;7:389397.
23. Hauer-Jensen M, Sauer T, Devik F, Nygaard K. Late changes following single dose roentgen irradiation of rat small intestine. Acta Radiol Oncol 1983:22:299-303.
24. Langberg CW, Sauer T, Reitan JB, Hauer-Jensen M. Tolerance of rat small intestine 1o localized single dose and fractionated irradiation. Acta Oncol 1992:31:781-787.
25. Langberg CW, Sauer T, Reitan JB, Hauer-Jensen M. Relationship between intestinal fibrosis and histopathologic and morphometric changes in consequential and late radiation enteropathy. Acta Oncol 1996:35:81-87.
26. Scott BR, Langberg OW, Hauer-Jensen M. Models for estimating the risk of ulcers in :he small intestine after localized single or fractionated irradiation. Br J Radiol 1995:68:49-57.
27. Enerbäck L. Mast ce Is in rat gastrointestinal mucosa. I. Effects of fixation. Acta Pathol Microbiol Scand 1966:66:289-302.
28. Matsson L. Mast cell heterogeneity in various oral mucosal sites in the rat. Arch Oral Biol 1992:37:445-450.
29. Baddeley AJ, Gundeisen HJG, Cruz-Orive LM. Estimation of surface area from vertical sections. J Microsc 1986;142:259-276.
30. Krawisz JE, Sharon F', Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87:1044-1350.
31. Wang J, Yao A, Wang J-Y, Sung C-C, Fink LM, Hardin JW, HauerJensen M. cDNA cloning and sequencing, gene expression, and immunolocalization of thrombomodulin in the Sprague-Dawley rat. DNA Research 1999:6:57-62.
32. Lopez-de Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33:737-747.
33. Hauer-Jensen M, Sauer T, Sletten K, Reitan JB, Nygaard K. Value of hydroxyproline measurements in the assessment of late radiation enteropathy. Acta Radiol Oncol 1986;25:137-142.
34. Ruifrok ACC, Mason KA, Lozano G, Thames HD. Spatial and temporal patterns of expression of epidermal growth factor, transforming growth factor and transforming growth factor 1-3 and their receptors in mouse jejunum after radiation treatment. Radiât Res 1997;147:1-12.
35. Anscher MS, Jirtle RL. Role of transforming growth factor- and hepatocyte growth factor in late normal tissue effects of radiation. Radiât Oncol Invest 1994;1:305-313.
36. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor l. Nature 1990:346:371374.
37. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48:959-966.
38. Shah M, Foreman DM, Ferguson MWJ. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 1992;339:213-214.
39. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. Natural inhibitor of transforming growth factor protects against scarring in experimental kidney disease. Nature 1992;360:361-364.
40. Ferguson MW. Skin wound healing: transforming growth factor antagonists decrease scarring and improve quality. J Interferon Res 1994;14:303-304.
41. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H. Blockade of type transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sei U S A 1999;96: 2345-2349.
42. Epperly MW, Travis EL, Sikora C, Greenberger JS. Magnesium Superoxide dismutase (MnSOD) plasmid/liposome pulmonary radioprotective gene therapy: modulation of irradiation-induced mRNA for IL-1, TNF-, and TGF- correlates with delay of organizing alveolitis/fibrosis. Biol Blood Marrow Transplant 1999;5: 204-214.
43. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Bürge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259.
44. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 1986; 137:3855-3860.
45. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor by human T lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 1986:163:1037-1050.
46. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS. Effects of transforming growth factor on the functions of natural killer cells: depressed cytolytic activity and blunting of Interferon responsiveness. J Immunol 1986;136:3916-3920.
47. Ravitz MJ, Wenner CE. Cyclin-dependent kinase regulation during Gl phase and cell cycle regulation by TGF-. Adv Cancer Res 1997:71:165-207.
48. Ashcroft GS, Yang X, Glick A, Weinstein M , Letterio JJ, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. Mice lacking SmadS show accelerated wound healing and an impaired local inflammatory resonse. Nat Cell Biol 1999:1:260-266.
49. Richter KK, Fagerhol MK, Carr JC, Winkler JM, Sung C-C, Hauer-Jensen M. Association of granulocyte transmigration with structural and cellular parameters of injury in experimental radiation enteropathy. Radiât Oncol Investig 1997;5:275-282.
50. Parekh T, Saxena B, Reibman J, Cronstein BN, Gold LI. Neutrophil chemotaxis in response to TGF- isoforms (TGF-l, TGF-2, TGF3) is mediated by fibronectin. J Immunol 1994:152:24562466.
51. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Alien R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T. Targeted disruption of the mouse transforming growth factor-l gene results in multifocal inflammatory disease. Nature 1992;359: 693-699.